Reunion Neuroscience Completes Take-Private Setup: Delisting & Consideration Details
Portfolio Pulse from Lara Goldstein
Reunion Neuroscience (NASDAQ:REUN) and MPM BioImpact have completed their plan of arrangement for MPM’s acquisition of Reunion for approximately $13.1 million. Shareholders approved the transaction and all holders of Reunion’s outstanding common shares are entitled to receive $1.12 in cash for each share held. Reunion’s shares are to be delisted from the Toronto Stock Exchange and the NASDAQ. The company is also applying to cease to be a reporting issuer under applicable Canadian securities laws.
August 04, 2023 | 10:14 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Reunion Neuroscience has been acquired by MPM BioImpact for $13.1 million and its shares will be delisted from the NASDAQ and Toronto Stock Exchange.
The acquisition of Reunion Neuroscience by MPM BioImpact and the subsequent delisting of its shares from the NASDAQ and Toronto Stock Exchange will likely lead to a decrease in the stock's liquidity and potentially its price. This is because delisting often results in a decrease in the visibility and attractiveness of a stock to investors.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100